Reconsidering tolerability of cancer treatments: opportunities to focus on the patient.
作者信息
Peipert John Devin, Smith Mary Lou
机构信息
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 625 Michigan Ave, 21st Floor, Chicago, IL, 60611, USA.
Research Advocacy Network, Chicago, IL, USA.
出版信息
Support Care Cancer. 2022 May;30(5):3661-3663. doi: 10.1007/s00520-021-06700-0. Epub 2022 Jan 11.
Abstract
摘要
相似文献
1
Reconsidering tolerability of cancer treatments: opportunities to focus on the patient.重新审视癌症治疗的耐受性：关注患者的契机。
Support Care Cancer. 2022 May;30(5):3661-3663. doi: 10.1007/s00520-021-06700-0. Epub 2022 Jan 11.
2
Correction to: Reconsidering tolerability of cancer treatments: opportunities to focus on the patient.对《重新审视癌症治疗的耐受性：关注患者的机会》的更正
Support Care Cancer. 2022 Sep;30(9):7817. doi: 10.1007/s00520-022-07276-z.
3
Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review.辅酶Q10对提高癌症治疗耐受性的疗效：一项系统评价
J Clin Oncol. 2004 Nov 1;22(21):4418-24. doi: 10.1200/JCO.2004.02.034.
4
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.在肿瘤学试验中使用 PRO 措施来了解耐受性：对临床审查、IND 安全性报告和临床现场检查的影响。
Clin Cancer Res. 2018 Apr 15;24(8):1780-1784. doi: 10.1158/1078-0432.CCR-17-2555. Epub 2017 Dec 13.
5
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics.更多并不一定更好：在靶向癌症治疗时代重新考虑早期临床试验设计。
Mol Oncol. 2023 Mar;17(3):382-383. doi: 10.1002/1878-0261.13391. Epub 2023 Feb 15.
6
Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening: The future of PSA screening by reconsidering prostate cancer mortality.关于：重新审视前列腺癌死亡率——PSA筛查的未来：通过重新审视前列腺癌死亡率来探讨PSA筛查的未来。
Eur Urol. 2020 Dec;78(6):929. doi: 10.1016/j.eururo.2020.06.028. Epub 2020 Jul 1.
7
Reconsidering Otto Warburg's glycolytic shift: pyrimidine derivatives are effective for the treatment of tumors exerting aerobic glycolysis.重新审视奥托·瓦尔堡的糖酵解转变：嘧啶衍生物对治疗进行有氧糖酵解的肿瘤有效。
Panminerva Med. 2022 Dec;64(4):567-568. doi: 10.23736/S0031-0808.22.04658-4. Epub 2022 Feb 4.
8
Evolution of the concept of focal therapy for prostate cancer.前列腺癌局部治疗概念的演变。
Oncology (Williston Park). 2013 Jan;27(1):64-8, 70; discussion 70.
9
[Special issue PRO] Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework.[特刊PRO] 基于估计量框架，考虑使用患者报告的癌症治疗相对耐受性终点。
J Biopharm Stat. 2024 Feb 15:1-19. doi: 10.1080/10543406.2024.2313060.
10
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.使用患者报告的结局测量来告知癌症治疗的耐受性：FDA 和关键路径研究所研讨会的总结。
Value Health. 2018 Jun;21(6):742-747. doi: 10.1016/j.jval.2017.09.009. Epub 2017 Nov 7.
引用本文的文献
1
Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.使用癌症治疗功能评估项目GP5评估耐受性：来自LIBRETTO-531的心理测量学证据，一项塞尔帕替尼治疗甲状腺髓样癌的3期试验
J Patient Rep Outcomes. 2024 Dec 19;8(1):149. doi: 10.1186/s41687-024-00823-8.
2
Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data.青少年和青年淋巴瘤患者治疗结果认知中的关键差距：当前数据综述
EJHaem. 2023 Aug 25;4(4):927-933. doi: 10.1002/jha2.778. eCollection 2023 Nov.
3
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.低级别和中级别不良事件对患者治疗体验和治疗中断的重要性：E1912 试验分析。
J Clin Oncol. 2024 Jan 20;42(3):266-272. doi: 10.1200/JCO.23.00377. Epub 2023 Oct 6.
本文引用的文献
1
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）的综合分级算法。
Clin Trials. 2021 Feb;18(1):104-114. doi: 10.1177/1740774520975120. Epub 2020 Dec 1.
2
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.使用患者报告的结局测量来告知癌症治疗的耐受性：FDA 和关键路径研究所研讨会的总结。
Value Health. 2018 Jun;21(6):742-747. doi: 10.1016/j.jval.2017.09.009. Epub 2017 Nov 7.
3
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).患者报告的早期治疗中断预测因素：NCIC 临床试验组（CCTG）MA.27（E1Z03）中随机分配至阿那曲唑或依西美坦的绝经后女性原发性乳腺癌的与治疗相关的症状和健康相关的生活质量。
Breast Cancer Res Treat. 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17.
4
Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.癌症治疗副作用患者报告的单一项目测量的有效性和有用性。
Cancer. 2018 Mar 1;124(5):991-997. doi: 10.1002/cncr.31133. Epub 2017 Nov 13.
5
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
Zotero 插件